Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Controlled Clinical Trial
. 2015 Jun;30(6):688-93.
doi: 10.3346/jkms.2015.30.6.688. Epub 2015 May 13.

Comparison of Arbekacin and Vancomycin in Treatment of Chronic Suppurative Otitis Media by Methicillin Resistant Staphylococcus aureus

Ji-Hee Hwang  1 , Ju-Hyung Lee  2 , Jeong-Hwan Hwang  3 , Kyung Min Chung  4 , Eun-Jung Lee  5 , Yong-Joo Yoon  6 , Mi-Kyoung Moon  1 , Ju-Sin Kim  1 , Kyoung-Suk Won  1 , Chang-Seop Lee  7
Affiliations
Controlled Clinical Trial

Comparison of Arbekacin and Vancomycin in Treatment of Chronic Suppurative Otitis Media by Methicillin Resistant Staphylococcus aureus

Ji-Hee Hwang et al. J Korean Med Sci. 2015 Jun.

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) is a major cause of ear infections. We attempted to evaluate the clinical usefulness of arbekacin in treating chronic suppurative otitis media (CSOM) by comparing its clinical efficacy and toxicity with those of vancomycin. Efficacy was classified according to bacterial elimination or bacteriologic failure and improved or failed clinical efficacy response. Ninety-five subjects were diagnosed with CSOM caused by MRSA. Twenty of these subjects were treated with arbekacin, and 36 with vancomycin. The bacteriological efficacy (bacterial elimination, arbekacin vs. vancomycin: 85.0% vs. 97.2%) and improved clinical efficacy (arbekacin vs. vancomycin; 90.0% vs. 97.2%) were not different between the two groups. However, the rate of complications was higher in the vancomycin group (33.3%) than in the arbekacin group (5.0%) (P=0.020). In addition, a total of 12 adverse reactions were observed in the vancomycin group; two for hepatotoxicity, one for nephrotoxicity, eight for leukopenia, two for skin rash, and one for drug fever. It is suggested that arbekacin be a good alternative drug to vancomycin in treatment of CSOM caused by MRSA.

Keywords: Arbekacin; Methicillin-resistant Staphylococcus aureus; Otitis Media; Vancomycin.

PubMed Disclaimer

Conflict of interest statement

DISCLOSURE: The authors have no conflicts of interest to disclose.

References

    1. Lee SH, Park CW, Tae K, Park IB, Hue YD, Kang JO, Kim JW. Comparative analysis of therapeutic effect between topical vancomycin and systemic vancomycin in otorrhea by methicillin-resistent Staphylococcus aureus (MRSA) infection. Korean J Otolaryngol-Head Neck Surg. 1999;42:704–708.
    1. Lee ES, Song JS, Hwang SJ, Suh HK, Cheong HJ. Possibility of reciprocal infection of methicillin-resistant Staphylococcus aureus between medical personnel and patients undergoing middle ear surgery. ORL J Otorhinolaryngol Relat Spec. 2001;63:87–91. - PubMed
    1. Hwang JH, Tsai HY, Liu TC. Community-acquired methicillin-resistant Staphylococcus aureus infections in discharging ears. Acta Otolaryngol. 2002;122:827–830. - PubMed
    1. MacNeil SD, Westerberg BD, Romney MG. Toward the development of evidence-based guidelines for the management of methicillin-resistant Staphylococcus aureus otitis. J Otolaryngol Head Neck Surg. 2009;38:483–494. - PubMed
    1. Wang G, Hindler JF, Ward KW, Bruckner DA. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J Clin Microbiol. 2006;44:3883–3886. - PMC - PubMed

Publication types

MeSH terms